Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

Vestre Viken Hospital Trust

Status: Unknown

Conditions: EDSS 4-7; Multiple Sclerosis

Treatments: Drug: Fampyra

Study type: Observational

Funder types: Other

Identifiers

NCT01720849

FampyraCSS

Details and patient eligibility

About

The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating.

Exclusion criteria

MS patients with contraindications to the compound according to the prescription guidelines.

Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months

Trial design

50 participants in 1 patient group

Fampyra group

Treatment:

Drug: Fampyra